GSK is accused of trying to suppress editorial on rosiglitazoneBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2654 (Published 19 May 2010) Cite this as: BMJ 2010;340:c2654
- Janice Hopkins Tanne
- 1New York
GlaxoSmithKline faces several new issues over its drug rosiglitazone (Avandia) and possible cardiovascular problems.
The company has had to answer reports that it had asked the European Heart Journal not to publish in print an online editorial that was critical of the drug. It was also reported to have settled lawsuits relating to rosiglitazone and has faced calls for the US Food and Drug Administration to stop an international trial and demands from members of Congress asking why the drug had not been recalled.
The company denied charges, first reported at www.cardiobrief.org, that it had tried to prevent the European Heart Journal from publishing in its print edition an online editorial, “The rise and fall of rosiglitazone,” by Steven Nissen of the Cleveland Clinic (2010;31;773-6, doi:10.1093/eurheartj/ehq016). In 2007 Dr Nissen raised the issue of possible cardiovascular problems with rosiglitazone in a paper in the New England Journal of Medicine (2007;356:2457-71).
GlaxoSmithKline’s head of research and development, Moncef Slaoui, wrote to the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial